Chapter 39: Purine and Pyrimidine Metabolism

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

How does your body actually conjure the very blueprints of life, you know, those intricate molecules that make up your DNA and RNA?

It's not just some abstract idea.

It's this constant, remarkably complex biochemical ballet happening inside you right now.

Today we're taking a deep dive into the really fascinating world of Purin and Pyrimidine metabolism.

And for this deep dive, we're grounding ourselves in a foundational chapter from Mark's basic medical biochemistry.

Our goal, really, is to give you a clear, accessible, and hopefully truly insightful understanding of these absolutely crucial biochemical pathways.

We're going to try and demystify how your body builds these vital molecules, basically from scratch, how it cleverly recycles them, and how it eventually breaks them down.

And along the way, we'll highlight the key concepts, the dance of the enzymes involved, and some really surprising clinical connections when things go a bit wrong.

You might think, okay, these building blocks probably just come from what you eat, right?

But here's where it gets super interesting.

Your body actually has to make most of them itself, from the ground up.

That's a process called de novo synthesis,

or it can be really efficient and reuse existing ones through what are called salvage pathways.

We're going to explore why getting this balance right between making new stuff and recycling the old is so critical for, well, pretty much everything, from powering your cells to keeping your immune system working properly.

That's a fantastic point to start with, because when we talk about nucleotides, it's so easy to just think DNA and RNA, full stop.

But what's truly amazing here is how much more they do.

Their roles go way, way beyond just being the letters in our genetic code.

You could almost think of them as metabolic multitaskers, constantly juggling different critical jobs inside the cell.

Like what, though?

What else are they up to besides just carrying genetic information?

Well, okay, first, yes, they absolutely are the activated precursors for making DNA and RNA that's foundational.

But they also form the core structure of essential coenzymes, things like NAD plus COBEA, FAD, coenzyme A.

These are absolute workhorses for countless metabolic reactions all over your body.

And of course, they are the cell's energy currency.

Think ATP and GDP.

Your cells literally cannot function without them.

Wow.

Okay, so not just information carriers, but energy carriers, too.

That's a lot of responsibility for one type of molecule.

Exactly.

And it doesn't stop there.

They act as activated intermediates in loads of other biosynthetic pathways.

For example, you need UDP glucose to make glycogen, which is how you store glucose, and S -Adenosylmethionine, or SAM, that's crucial for methylation reactions, vital for controlling genes and modifying proteins.

Plus, they're key signaling molecules, acting as second messengers.

Things like cyclic AMP, CAM -MP, and cyclic GMP, see GMP,

they're how cells talk to each other internally.

And as if that wasn't enough, they're also allosteric regulators.

They help control enzyme activity based on how much energy the cell has.

I mean, anyone who's looked at a metabolic pathway chart has seen enzymes being turned on or off by ATP, ADP, or AMP, right?

So when you consider all these incredibly diverse, absolutely critical roles, it becomes crystal clear why your body can't just rely on the tiny amounts you might get from food.

That's why understanding both de novo synthesis and these clever salvage pathways is just so vital.

We've definitely established how indispensable these molecules are.

So let's pull back the curtain.

How does your body actually craft them?

Let's start with that big one.

The nobo -puring synthesis, this sounds like a massive undertaking.

How much energy does it really cost, and where does this mostly happen?

Oh, it is massive.

It's incredibly energy hungry.

You're looking at needing six molecules of ATP for every single purine molecule you make.

Yeah, imagine that investment.

And where does the bulk of this happen?

Primarily in your liver.

Makes sense, given its role as the body's metabolic hub.

So to walk you through it, picture a really meticulous assembly line.

You gather the core ingredients, the precursors from various places in your metabolism.

You need amino acids like glycine, glutamine, and aspartate.

You even need carbon dioxide.

And a really vital one -carbon carrier called N10 -formyl tetrahydrofolate.

N10 -formyl tetrahydrofolate, that's quite a name.

What exactly is its job here?

Yeah, right.

It's a key player in what we call one -carbon metabolism.

Basically, it carries and donates single carbon atoms that are needed to build complex molecules, like our purine ring.

So it's bringing in specific building blocks.

Now, the whole pathway really kicks off with an activated form of the sugar ribose, called 5 -phosphorbosyl -1 -or -pigrophosphate.

Let's just call it PRPP.

Think of PRPP as the primed platform onto which everything else gets built.

OK, so you've got PRPP.

But I remember you saying PRPP is used in other pathways too, right?

So making PRPP isn't the point of no return for making purines specifically.

What is that first really committed step?

The one that says, OK, we're definitely making a purine now.

And why is it so tightly controlled?

That's a really sharp observation.

And it gets right to a core principle of how metabolism is regulated.

You're right, PRPP is used elsewhere.

The true first committed step in purine building is when PRPP reacts with the amino acid glutamine.

This forms 5 -euro -phosphorbosyl -1 -or -amine.

This specific reaction is catalyzed by an enzyme called glutamine phosphorobesalaminotransferase.

And this is where the cell really commits.

It's basically saying, OK, this PRPP is now destined to become a purine.

And that's why this step is so highly regulated.

It stops the cell wasting a ton of energy making purines if it already has enough.

It's all about metabolic efficiency.

Makes sense.

So once that commitment is locked in, how do all those other pieces, the glycine, the folate derivative, CO2, aspartate, how do they actually come together to form the ring structure?

From that committed step onward, it's this very sequential, almost architectural buildup.

You can imagine these different components being added one by one, step by step.

The entire glycine molecule slots in.

N10 formal tetrahydrofolate adds a carbon.

Glutamine donates a nitrogen.

CO2 gets incorporated.

Aspartate contributes atoms, too.

They're all meticulously added, contributing specific atoms and eventually closing the ring structure.

It's like assembling a complex piece of molecular machinery.

And the very first complete purine nucleotide that rolls off this assembly line is inosine monophosphate, or IMP.

This one contains the base hypoxanthine.

IMP.

I think I've heard of that one.

Doesn't it have something to do with wobble base pairing and RNA?

Exactly.

You got it.

While hypoxanthine isn't usually found in DNA, its presence in IMP, and consequently in some tRNA molecules,

allows for that wobble.

It's basically a bit of flexibility in base pairing at the third position of a codon, letting one tRNA recognize multiple codons.

Pretty neat trick for efficiency in making proteins.

But what's also really crucial is that IMP then acts as a branch point.

It's the precursor for both AMP, adenosine monophosphate, and GMP, guanosine monophosphate.

To make AMP, aspartate donates a nitrogen.

And interestingly, this step needs GTP, not ATP, for energy.

Then fumarate is released.

To make GMP, the hypoxanthine base in IMP gets oxidized to xanthine, forming XMP first.

Then glutamine donates another nitrogen to make GMP, and this reaction requires ATP.

Okay, so you get AMP and GMP, and then I guess they need more phosphates added to become the ATP and GTP we know as energy currency and RNA -built edlox.

Precisely.

AMP and GMP are then further phosphorelated, adding more phosphate groups to get to their diphosphate forms, ATP, GTP, and finally their triphosphate forms, ATP, GTP.

That makes them ready for all their various cellular jobs, including, yes, being incorporated into RNA.

So you can really see how complex and how energy demanding this whole de novo process is.

It's like this incredibly finely tuned assembly line, making sure the cell has just the right amounts of both AMP and GMP.

Given that incredibly high energy cost, I mean, six ATPs per purine feels like driving a gas guzzler just to get milk.

It makes total sense the body would have backup plans, right?

This must be where those purine salvage pathways come in, like a clever recycling program, reusing existing purine parts instead of building everything new.

Absolutely.

It's biochemical recycling at its best, hugely efficient.

The salvage pathways let the cell interconvert free purine bases, their nucleosides, and the nucleotides themselves.

There are a few key enzymes doing the work here.

One is purine nucleoside phosphorylase.

It takes nucleosides like guanosine and inosine and breaks them down into the free bases guanine and hypoxanthine plus ribose -1 -phosphate.

Then you have the phosphoribosol transferases.

There's APRT, which handles adenine, and HGPRT, which handles hypoxanthine and guanine.

These enzymes are like molecular mechanics.

They reattach a ribose -5 -phosphate group, which comes from PRPP, back onto that free base, efficiently making a new nucleotide again.

And what about adenosine deminase, ADA?

What's its role and why is it especially important for certain types of cells?

Right.

AD is another key player.

It converts adenosine into inosine, and it can also convert AMP into IMP.

And it's really crucial to mention, especially for some cells like lymphocytes,

your key immune cells salvage isn't just a backup plan.

For them, it's the main way they get their nucleotides.

So these salvage pathways are absolutely fundamental for a healthy immune system.

There's also a specific cycle, the purine nucleotide cycle, that's particularly active in muscle.

In this cycle, aspartate gets deaminated to fumarate, which is useful because fumarate can feed into the TCA cycle, helping muscle generate more energy during intense exercise.

Okay.

And this is where we really start to connect the biochemistry to the clinic, right?

When these recycling systems or the enzymes involved fail.

Let's talk about Lesch -Nyhan syndrome.

Yes.

Lesch -Nyhan is a really severe and honestly heartbreaking genetic condition.

It's caused by a faulty HGPRT enzyme, the one that recycles hypoxanthine and guanine.

Without a working HGPRT, the body can't salvage these bases.

Instead, they get shunted into the degradation pathway, leading to a massive overproduction of uric acid.

This causes severe gout, often very early in life.

But what's really tragic and unique about Lesch -Nyhan are the devastating neurological symptoms.

We see developmental delays, significant intellectual disability, and these very characteristic, distressing, self -injurious behaviors like compulsive biting and headbanging.

It starkly highlights just how critical these seemingly simple salvage pathways are, especially for the brain, which has such high metabolic demands.

And then there's the other major one you mentioned, adenosine deminus, or ADA deficiency.

This leads to SCID, severe combined immunodeficiency.

Right.

In ADA deficiency, the lack of this enzyme causes a buildup of its substrates, particularly deoxydenosine.

This gets phosphorylated to DATP.

The problem is, high levels of DATP, especially within lymphocytes, act as a potent inhibitor of another critical enzyme called ribonucleotide reductase.

This enzyme, as we'll discuss more later, is essential for making the deoxyribonucleotides needed for DNA synthesis.

So if it's inhibited, DNA synthesis basically shuts down in these rapidly dividing immune cells.

This leads to the death of lymphocytes, T cells, and B cells primarily, resulting in a severely compromised immune system.

That's SCID.

Individuals are incredibly vulnerable to infections.

There are some other ideas about how it's toxic too, maybe involving inhibition of another enzyme called SAH hydrolase, or over -activating adenosine receptors.

But the main hit is on DNA synthesis in immune cells.

Okay, let's switch gears now.

We've covered purines.

What about the other family?

The pyrimidines, still essential, but you mentioned their synthesis follows a different kind of strategy.

How so?

That's a great point of contrast.

It's quite different.

Unlike purines, where you build the ring structure onto the activated ribose sugar

you build the base first as a free ring structure, and then you attach the ribose 5 -O phosphate from PRPP.

The key starting materials, the precursors for the pyrimidine ring itself, are the amino acid aspartate and a molecule called carbamoyl phosphate.

And the initial regulated step, the committed step for pyrimidine synthesis, is making that carbamoyl phosphate.

This happens in the cytoplasm using glutamine, bicarbonate, from CO2, and ATT.

The enzyme responsible is carbamoyl phosphate synthetase II, or CPSII.

Okay, CPSI.

So that's different from CPSI, the one we talked about in the urea cycle, right?

Different location, different nitrogen source.

Exactly.

Good connection.

CPSII is distinct.

It's in the cytoplasm, and it uses the nitrogen from glutamine.

CPSI is mitochondrial and uses free ammonia for the urea cycle.

So once you have this cytoplasmic carbamoyl phosphate, it combines with aspartate.

The ring structure then closes up, undergoes an oxidation step to form erotic acid.

Then PRPP comes in and a ribose phosphate is attached, forming erotidine 5 -orophosphate, or OMP.

Finally, OMP is decarboxylated.

A CO2 is removed to yield the first main, pyrimidine nucleotide, uridine monophosphate, or UMP.

This UMP is sort of the central hub for making other pyrimidines.

And I heard that in mammals, some of these enzyme steps are actually physically linked together on single protein chains.

Sounds very organized.

It is.

It's quite elegant, really.

In mammals, the first three enzymes in the pathway CPSII,

aspartate, transcarbamoylase, and diagerotase, are all part of one large polypeptide chain called CAD.

And the last two steps, attaching the PRPP and the decarboxylation, catalyzed by orotate phosphorobiciltransferase and OMP decarboxylase, are on another single polypeptide called UMP synthase.

Having them physically linked like this in these multi -enzyme complexes probably makes the whole process much more efficient by channeling the intermediates directly from one active site to the next.

And from UMP, the cell can then make cytidine triphosphate, needed for RNA and other things, and also deoxythymidine, monophosphate, DTMP, the T needed for DNA.

And just like with purines, when paramedy metabolism goes awry, we see specific clinical conditions pop up.

We do.

A classic example is hereditary erotic aciduria.

This is a rare genetic disorder caused by defects in that UMP synthase enzyme complex we just mentioned.

If UMP synthase isn't working properly, the cell can't make UMP efficiently.

Erotic acid, an intermediate just before UMP synthase acts, builds up and gets excreted in the urine, hence the name.

Because you can't make pyrimidines properly, you see problems like impaired growth and anemia.

The really interesting thing is that you can treat this effectively by giving the patient oral uridine.

Uridine can be salvaged, phosphorelated to UMP, essentially bypassing the block and providing the pyrimidines the body needs.

And there's that other really neat connection you hinted at earlier between a urea cycle problem and pyrimidine synthesis, almost like a traffic jam spilling over onto another road.

That's a perfect analogy, yes.

Ornithine transcarbomoyolase deficiency, or OTC deficiency, that's a urea cycle disorder.

Normally, carbamoyl phosphate, made in the mitochondria by CPSI, enters the urea cycle via OTC.

If OTC is deficient, this mitochondrial carbamoyl phosphate builds up.

Some of it then leaks out into the cytoplasm.

Now, this excess carbamoyl phosphate in the cytoplasm essentially floods the pyrimidine pathway, bypassing the normal regulation point at CPSII.

This drives excessive pyrimidine synthesis, leading to a buildup and excretion of erotic acid again.

So it's an acquired erotic aciduria, secondary to a urea cycle defect.

It really highlights how interconnected everything is.

Right, so we've covered making the ribonucleotides the A, G, C, and U for RNA.

But what about DNA?

It needs deoxyribonucleotides, DTP, DGTP, DCTP, and DTP.

How does the body make that switch, removing that one oxygen atom from the ribose sugar?

This is another absolutely critical conversion step, moving from the riboform to the deoxyriboform needed for DNA.

The star player here is an enzyme called ribonucleotide reductase.

Its job is specifically to reduce the ribose sugar, removing the hydroxyl group at the 2' position to make it deoxyribose.

Importantly, this reaction happens at the diphosphate level.

So it converts ADP, GDP, CDP, and UDP into DADP, DGDP, DCDP, and DUDP respectively.

And to do this reduction, it needs electrons, which are supplied by a small protein called thyridoxin.

Okay, so it's not just a simple swap.

You mentioned it's tightly controlled.

How does the cell make sure it has the right balance of all four deoxy building blocks for DNA?

Getting that wrong sounds like it would be catastrophic for replication.

Absolutely catastrophic.

The regulation here is incredibly sophisticated, really beautiful biochemistry.

Ribonucleotide reductase has two main allosteric control sites.

Think of them as regulatory dials.

The first dial controls the overall activity of the enzyme.

ATP binding turns the enzyme on N, signaling that there's enough energy and building blocks available.

But DATP, deoxydenosine, triphosphate binding, turns the enzyme O off.

This is crucial feedback inhibition.

If you have enough deoxy A, you shut down production of all deoxyribonucleotides to prevent imbalances.

The second dial controls substrate specificity.

This site determines which of the four ribonucleotide diphosphates, ADP, GDP, CDP, UDP, the enzyme actually binds and reduces at any given time.

Different deoxyribonucleotides binding to this site change the enzyme's preference.

For example,

when DTTP, deoxythiametide, triphosphate builds up, it signals the enzyme to reduce GDP preferentially.

When DTTP builds up, it signals the enzyme to reduce ADP.

It's this incredibly intricate balancing act, ensuring the cell produces roughly equal amounts of all four DTTPs needed for accurate DNA synthesis.

Wow, okay, that's complex.

And what about DTMP, the T in DNA?

You mentioned the enzyme works on UDP.

How does that become the T?

Right, so ribonucleotide reductase makes DUDP or DCDP, which can be converted to DUDP.

Then DUDP is converted to DUMP, deoxyuridinamotophosphate.

Finally, DUMP is methylated.

A methyl group is added to become DTMP.

This methylation step requires another derivative of tetrahydrofolate, specifically N5000, N -pethylene, N -tetrahydrofolate.

All these deoxy forms, DADP, DBB, DCDP, DDDMP, are then phosphorylated to their triphosphate forms.

DATP, DGTP, DCDP, DTTP, making them ready for DNA polymerase.

This whole conversion and balancing act by ribonucleotide reductase is absolutely essential for cell division and growth.

If this step fails, DNA synthesis stops dead.

Okay, so they're built, they're used, they're maybe recycled.

But eventually, these molecules reach the end of their useful life.

How does the body finally dispose of them?

And I hear purines and pyrimidines are treated very differently here.

That's a really key distinction, yes.

They have very different fates.

For purines, the As and Gs, the final end product of degradation in humans is uric acid.

This breakdown happens mostly in the liver.

If you trace the pathway, AMP usually gets deaminated to IMP first.

Then both IMP and GMP have their phosphate groups removed, and then the ribose sugar is cleaved off, leaving the free bases hypoxanthine from IMP and guanine from GMP.

Both hypoxanthine and guanine are then converted into an intermediate called xanthine.

Hypoxanthine is converted by xanthine oxidase, while guanine is converted by an enzyme called guanase.

Finally, xanthine itself is ex -guan again by xanthine oxidase, which converts it into uric acid.

And that's where the gout problem comes in, isn't it?

Uric acid.

Exactly.

Uric acid isn't very soluble in water or in blood and bodily fluids.

If levels get too high, either because you're producing too much or not excreting enough, it can crystallize out, especially in cooler areas like joints, particularly the big toe.

These sharp monosodium ureate crystals trigger a painful inflammatory response.

That's gout.

And it's worth noting again, the body gets very little energy back from breaking down purines.

It really reinforces why salvage is the preferred, more economical route.

Okay, so purines end up as potentially problematic uric acid.

What about the pyrimidines C, U, and T?

Are they broken down into anything troublesome?

Nope.

Completely different story.

Pyrimidines are broken down into highly water -soluble compounds.

Things like beta -alanine, beta -aminosobutyrate, ammonia, which becomes urea, and carbon dioxide.

These are all easily handled and excreted by the body, mainly in the urine.

They don't build up or crystallize.

So even if pyrimidine breakdown increases, it generally doesn't cause any disease states.

Much less dramatic end -of -life pathway.

This brings us back perfectly to Lada T, the case study example, who had that excruciating gout attack.

Her doctor put her on allopurinol.

How exactly does that drug work to help her?

Allopurinol is a really classic effective treatment for gout.

It works by targeting that key enzyme in uric acid production, xanthine oxidase.

Allopurinol is what we call a suicide inhibitor.

It looks a bit like hypoxanthine, so xanthine oxidase binds to it.

The enzyme starts to process it but gets stuck, effectively inactivating itself.

By inhibiting xanthine oxidase, allopurinol blocks those final two steps.

The conversion of hypoxanthine to xanthine and xanthine to uric acid.

So instead of building up pearly soluble uric acid, the body accumulates more hypoxanthine and xanthine.

These are much more soluble and easier to excrete, so they don't crystallize in the joints.

And there's a bonus effect.

Because you now have more hypoxanthine and guanine available, since they aren't being fully degraded, the salvage pathways, particularly HGPRT, become more active.

This increased salvage uses up PRPP.

Lower PRPP levels then send the signal back to decrease the rate of de novo curing synthesis.

So allopurinol tackles the problem from both ends, less production, more recycling.

That's clever.

So it's not just blocking the end product, but actually feeding back to reduce the initial synthesis too.

You also mentioned gout can happen in other conditions, like von Gierke's disease.

How is that linked?

Right.

And another great example of pathway crosstalk.

Von Gierke's disease is a glycogen storage disease caused by a deficiency in glucose 6 -phosphatase.

This leads to a buildup of glucose 6 -phosphate in the liver.

Glucose 6 -phosphate is the entry point for the pentose phosphate pathway, which produces ribose 5 -phosphate.

More glucose 6 -phosphate means more flux through the pentose phosphate pathway, meaning more ribose 5 -phosphate.

And more ribose 5 -phosphate means more PRPP synthesis.

As we saw, high PRPP levels drive up de novo purine synthesis.

More purines being made means more purines eventually get degraded, leading to higher uric acid production and consequently gout.

Understanding these connections isn't just academic.

It has huge clinical relevance, not only for diagnosing and treating metabolic disorders like gout or SCID, but also for developing therapies.

Think about anti -cancer drugs.

Many of them, like 5 -fluorosil or methotrexate, often part of regimens like RCHOP for lymphoma, specifically target nucleotide synthesis pathways to stop rapidly dividing cancer cells from making the DNA and RNA they need to grow.

So as you can see, we've journeyed through these really intricate, elegant pathways of purine and purinine metabolism.

From how they're built from scratch de novo, how they're efficiently recycled, salvaged, the complex ways they're regulated, and finally how they're broken down.

We've seen how critical these processes are for literally everything.

Our energy, our genes, our immune defenses, and how disruptions can lead to significant diseases like gout and SCID.

It's really the fundamental part of cellular life.

It really is fascinating, isn't it?

How understanding these microscopic molecular dances gives us such a powerful window into overall human health and disease.

It definitely makes you wonder how many other incredibly subtle, interconnected pathways are constantly working away inside us, keeping everything running, and how much more there still is to discover.

Definitely keep that curiosity going.

We really hope this sneak dive today has given you a solid, understandable foundation for exploring this area further.